The gut hormone glucagon-like peptide-1 (GLP-1) and its analogues, which have been in clinical use for diabetes for over a decade, have useful appetite-suppressive effects and are now licensed for obesity. The gene discussed is GCG; the disease is obesity due to melanocortin 4 receptor deficiency.